Literature DB >> 27594411

Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.

Xuechao Wan1, Wenhua Huang1, Shu Yang1, Yalong Zhang1, Pu Zhang1, Zhe Kong1, Tao Li2, Hai Wu1, Fengxiang Jing3, Yao Li4.   

Abstract

Prostate cancer (PCa) is the most commonly diagnosed and secondly leading cause of cancer death among males. But the precise mechanism of prostate cancer progression, including microRNAs (miRNAs) functioning in it, is still needs further study. We found miR-27a to be down-regulated in prostate cancer, and we investigated the mechanism and role of miRNA-27a in prostate cancer. MiR-27a, a transcriptional target of AR, was an androgen-induced miRNA in LNCaP cells. In castration-resistant prostate cancer (CRPC) cells, we for the first time reported that miR-27a was downregulated by PI3K signaling. MiR-27a functioned as a tumor suppressor in prostate cancer. Over-expression of miR-27a decreased prostate cancer cell proliferation and migration, and induced prostate cancer cell cycle arrest and apoptosis. MAP2K4, miR-27a's direct target gene, functioned as an oncogene in prostate cancer by reducing G1-S phase arrest and inhibiting cell apoptosis of prostate cancer cells. In conclusion, miR-27a functions as a tumor suppressor by suppressing MAP2K4 which acts as an oncogene in prostate cancer cell lines; we also provided a new mechanism of castration-resistant prostate cancer mediated by miR-27a that downregulation of miR-27a caused by aberrant AR signaling and PI3K/Akt signaling after androgen deprivation therapy (ADT) would promote the progression of castration-resistant prostate cancer.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADT; Androgen receptor; CRPC; PI3K signaling; microRNA

Mesh:

Substances:

Year:  2016        PMID: 27594411     DOI: 10.1016/j.biocel.2016.08.043

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  22 in total

1.  MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.

Authors:  Xiaozhen Wu; Zuode Gong; Lanying Sun; Long Ma; Qibao Wang
Journal:  Cell Prolif       Date:  2017-03-20       Impact factor: 6.831

2.  [Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].

Authors:  Shu Liu; Yi-Yi Liu; Rong Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

3.  ZNFX1 anti-sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c-Myc expression via a regulatory network of competing endogenous RNAs.

Authors:  Xiaolu Cui; Chiyuan Piao; Chengcheng Lv; Xuyong Lin; Zhe Zhang; Xiankui Liu
Journal:  Cell Mol Life Sci       Date:  2019-07-18       Impact factor: 9.261

4.  MiRNA-27a mediates insulin resistance in 3T3-L1 cells through the PPARγ.

Authors:  Yangming Zhuang; Ming Li
Journal:  Mol Cell Biochem       Date:  2022-01-24       Impact factor: 3.396

5.  Association of Androgenic Regulation and MicroRNAs in Acinar Adenocarcinoma of Prostate.

Authors:  Julio Guilherme Balieiro Bernardes; Marianne Rodrigues Fernandes; Juliana Carla Gomes Rodrigues; Lui Wallacy Morikawa Souza Vinagre; Lucas Favacho Pastana; Elizabeth Ayres Fragoso Dobbin; Jéssyca Amanda Gomes Medeiros; Leonidas Braga Dias Junior; Gabriel Monteiro Bernardes; Izabel Maria Monteiro Bernardes; Ney Pereira Carneiro Dos Santos; Samia Demachki; Rommel Mario Rodriguez Burbano
Journal:  Genes (Basel)       Date:  2022-03-30       Impact factor: 4.141

6.  MiR-27a rs895819 is involved in increased atrophic gastritis risk, improved gastric cancer prognosis and negative interaction with Helicobacter pylori.

Authors:  Qian Xu; Tie-Jun Chen; Cai-Yun He; Li-Ping Sun; Jing-Wei Liu; Yuan Yuan
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

7.  Co-expression analysis revealed PTCH1-3'UTR promoted cell migration and invasion by activating miR-101-3p/SLC39A6 axis in non-small cell lung cancer: implicating the novel function of PTCH1.

Authors:  Xuechao Wan; Zhe Kong; Kaili Chu; Chuanyou Yi; Jian Hu; Rui Qin; Chen Zhao; Fangqiu Fu; Hai Wu; Yao Li; Yan Huang
Journal:  Oncotarget       Date:  2017-12-13

Review 8.  Micrornas in prostate cancer: an overview.

Authors:  Daniela Vanacore; Mariarosaria Boccellino; Sabrina Rossetti; Carla Cavaliere; Carmine D'Aniello; Rossella Di Franco; Francesco Jacopo Romano; Micaela Montanari; Elvira La Mantia; Raffaele Piscitelli; Flavia Nocerino; Francesca Cappuccio; Giovanni Grimaldi; Alessandro Izzo; Luigi Castaldo; Maria Filomena Pepe; Maria Gabriella Malzone; Gelsomina Iovane; Gianluca Ametrano; Paola Stiuso; Lucio Quagliuolo; Daniela Barberio; Sisto Perdonà; Paolo Muto; Maurizio Montella; Piera Maiolino; Bianca Maria Veneziani; Gerardo Botti; Michele Caraglia; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-07-25

9.  Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression.

Authors:  Yuanqing Dai; Dongjie Li; Xiong Chen; Xinji Tan; Jie Gu; Mingquan Chen; Xiaobo Zhang
Journal:  Med Sci Monit       Date:  2018-05-25

10.  MicroRNA-19a acts as a prognostic marker and promotes prostate cancer progression via inhibiting VPS37A expression.

Authors:  Fangqiu Fu; Xuechao Wan; Dan Wang; Zhe Kong; Yalong Zhang; Wenhua Huang; Chenji Wang; Hai Wu; Yao Li
Journal:  Oncotarget       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.